{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/allergic-rhinitis/prescribing-information/oral-leukotriene-receptor-antagonists/","result":{"pageContext":{"chapter":{"id":"c871daa0-d649-59f1-b13c-79ab64e7083e","slug":"oral-leukotriene-receptor-antagonists","fullItemName":"Oral leukotriene receptor antagonists","depth":2,"htmlHeader":"<!-- begin field db18a75b-314a-4cb9-9dfa-a96800dd2f1e --><h2>Oral leukotriene receptor antagonists</h2><!-- end field db18a75b-314a-4cb9-9dfa-a96800dd2f1e -->","summary":"","htmlStringContent":"<!-- begin item c6a2453b-7398-4bd6-b605-a96800dd2ee3 --><!-- end item c6a2453b-7398-4bd6-b605-a96800dd2ee3 -->","topic":{"id":"e84371ef-9d30-56df-8358-1520fb2c324f","topicId":"0473d89c-2999-40d1-911f-d265b4bd3942","topicName":"Allergic rhinitis","slug":"allergic-rhinitis","lastRevised":"Last revised in September 2018","chapters":[{"id":"5fa28a05-233b-5de6-aee8-ea0327f3c7d6","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ea1f0c07-a5f8-599b-9b96-71ef8590b2a6","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"99b142c6-9593-51c7-9c86-7c8a537a3b8c","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"67cd9666-b198-574f-9fbf-cd740a7d8c3e","slug":"changes","fullItemName":"Changes"},{"id":"7d544db5-f3b7-5709-a2ae-076455d76d20","slug":"update","fullItemName":"Update"}]},{"id":"392391e3-b09a-5cab-ae2a-040eb039abd9","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"292568d8-a1f5-5b8f-a13d-f3c014fa8e95","slug":"goals","fullItemName":"Goals"},{"id":"2f7129b7-e08b-5e5f-997c-4b661ce0a778","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"8062582a-18e3-58d5-a8cb-f9689e259444","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"1e562233-ae40-5755-abc7-71551f4cea02","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ccab909c-169d-52aa-ac0a-9d425f89a99c","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"37d61d5d-e2f1-58ef-9c6a-27c4011784f3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"84432cb8-00ce-599e-9e05-3493755dacd6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"f59296af-8e0a-509d-b8f3-692efd2bdb92","slug":"definition","fullItemName":"Definition"},{"id":"37020833-afb2-529a-975a-1f1a7a5db2ef","slug":"causes","fullItemName":"Causes"},{"id":"962f75f0-d73d-5c7c-aaf4-d08fc672e6be","slug":"prevalence","fullItemName":"Prevalence"},{"id":"ab993d04-4c7b-59cd-9e56-2e0ef7fdc9db","slug":"complications","fullItemName":"Complications"},{"id":"68b348fd-2864-5da4-8687-6d8c25004f1b","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"80c9e7d3-3315-55b9-98fb-2261b95a1b5c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"3cc3ef09-2238-5504-8781-48914ad6a4c9","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"5a3f0e38-3f88-5049-beaa-f4cb26499dc6","slug":"assessment","fullItemName":"Assessment"},{"id":"5bd413c7-0398-5b71-acad-a5699c7c703b","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"9b8b1dfa-dfda-5292-a329-64d2c435a006","fullItemName":"Management","slug":"management","subChapters":[{"id":"a132cc60-bb1b-5679-8eda-db080a1e772a","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"760f3c4d-0984-5865-acbe-65d470f66518","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"a47a2aa5-0821-5bf5-987b-2397ac2c982f","slug":"intranasal-antihistamines","fullItemName":"Intranasal antihistamines"},{"id":"449809a3-a714-573e-a21f-8e4295eb984e","slug":"oral-antihistamines","fullItemName":"Oral antihistamines"},{"id":"5507fb81-aa18-5a21-b619-8db3c3c78e80","slug":"intranasal-cromones","fullItemName":"Intranasal cromones"},{"id":"5102b868-dccf-58c1-b6c7-3a59a24c6602","slug":"intranasal-decongestants","fullItemName":"Intranasal decongestants"},{"id":"623ba003-b473-5be2-bc25-e438f1500f7c","slug":"intranasal-anticholinergics","fullItemName":"Intranasal anticholinergics"},{"id":"c871daa0-d649-59f1-b13c-79ab64e7083e","slug":"oral-leukotriene-receptor-antagonists","fullItemName":"Oral leukotriene receptor antagonists"}]},{"id":"f3877d58-da5a-5655-8752-49e87f3a410b","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"87371e7f-8741-54ef-9af6-339f8f0b9285","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"318f5be9-46cf-5fb9-b28c-7ebb4a901904","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"49c3da95-9d4f-5a93-a7ca-e71965fcb981","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"33a2085c-95d6-5004-8f1f-50a08684c638","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"4b1a0d4a-fd5e-5b81-9293-5b2f004871cb","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"735b627c-7d7e-58b8-8196-b4972220342b","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"92889a85-b6e7-58f3-9f09-eae6ca76386c","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"760f3c4d-0984-5865-acbe-65d470f66518","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"0ade1921-e120-5dfe-a739-d990e6d3af4b","slug":"dose-regimens","fullItemName":"Dose regimens","depth":3,"htmlHeader":"<!-- begin field 21b1fd11-146a-4dfd-9738-a96b01170d51 --><h3>Dose regimens</h3><!-- end field 21b1fd11-146a-4dfd-9738-a96b01170d51 -->","summary":"","htmlStringContent":"<!-- begin item 9fb259b9-7439-4777-bd37-a96b01170d20 --><!-- begin field 75f07660-6e73-4a5d-8a3c-a96b01170d51 --><ul><li><strong>Oral montelukast is licensed for the symptomatic relief of seasonal allergic rhinitis in people with asthma.</strong><ul><li>For children aged 15–17 years and adults — 10 mg once daily, dose to be taken in the evening.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF 76, 2018</a>] </p><!-- end field 75f07660-6e73-4a5d-8a3c-a96b01170d51 --><!-- end item 9fb259b9-7439-4777-bd37-a96b01170d20 -->","subChapters":[]},{"id":"88f75f70-78e6-5e3c-ae99-9dd83c0c2a0e","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 08c0948e-c5ae-4da9-ad58-a96800dd3c77 --><h3>Contraindications and cautions</h3><!-- end field 08c0948e-c5ae-4da9-ad58-a96800dd3c77 -->","summary":"","htmlStringContent":"<!-- begin item 7589311a-f5d8-4d54-8ae7-a96800dd3bf0 --><!-- begin field dc474790-0994-40f0-82b1-a96800dd3c77 --><ul><li>There are no noted contraindications or cautions for prescribing oral montelukast.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF 76, 2018</a>]</p><!-- end field dc474790-0994-40f0-82b1-a96800dd3c77 --><!-- end item 7589311a-f5d8-4d54-8ae7-a96800dd3bf0 -->","subChapters":[]},{"id":"8d360ac7-239c-59a4-ba45-b615b7e25237","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 307a7d73-405f-40d5-84fb-a96800dd504d --><h3>Adverse effects</h3><!-- end field 307a7d73-405f-40d5-84fb-a96800dd504d -->","summary":"","htmlStringContent":"<!-- begin item beaf7535-522a-4ee7-aea4-a96800dd4fd8 --><!-- begin field 6e3aa8a4-6360-48aa-9533-a96800dd504d --><ul><li><strong>Possible adverse effects of oral montelukast include:</strong><ul><li>Abdominal pain, headache, hyperkinesia (in young children), thirst (common).</li><li>Abnormal dreams, aggressive behaviour, agitation, anxiety, arthralgia, bruising, depression, dizziness, drowsiness, dry mouth, dyspepsia, epistaxis, hostility, hypoaesthesia, irritability, malaise, muscle cramps, myalgia, oedema, paresthesia, psychomotor hyperactivity, restlessness, seizures, sleep disturbances, sleep-walking (uncommon).</li><li>Very rare, Churg-Strauss syndrome has occurred, sometimes following the reduction or withdrawal of oral corticosteroid therapy. Prescribers should be alert to the development of eosinophilia, vasculitic rash, worsening respiratory symptoms, cardiac complications, or peripheral neuropathy.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF 76, 2018</a>]</p><!-- end field 6e3aa8a4-6360-48aa-9533-a96800dd504d --><!-- end item beaf7535-522a-4ee7-aea4-a96800dd4fd8 -->","subChapters":[]},{"id":"fc1c05d7-5a1f-5b5d-ac26-1f9795c7b0e6","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 264f677f-c51f-468d-b55c-a96800dd5edc --><h3>Drug interactions</h3><!-- end field 264f677f-c51f-468d-b55c-a96800dd5edc -->","summary":"","htmlStringContent":"<!-- begin item 5eddcdb9-f4e9-47a5-85bf-a96800dd5ea4 --><!-- begin field 86b911e7-1caf-4cc6-a60f-a96800dd5edc --><ul><li><strong>Possible drug interactions with oral montelukast include:</strong><ul><li>Carbamazepine — carbamazepine is predicted to decrease the exposure to montelukast.</li><li>Clopidogrel — clopidogrel is predicted to moderately increase the exposure to montelukast.</li><li>Leflunomide — leflunomide is predicted to increase the exposure to montelukast.</li><li>Phenobarbital — phenobarbital is predicted to decrease the exposure to montelukast.</li><li>Phenytoin — phenytoin is predicted to decrease the exposure to montelukast.</li><li>Primidone — primidone is predicted to decrease the exposure to montelukast.</li><li>Rifampicin — rifampicin is predicted to decrease the exposure to montelukast.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF 76, 2018</a>] </p><!-- end field 86b911e7-1caf-4cc6-a60f-a96800dd5edc --><!-- end item 5eddcdb9-f4e9-47a5-85bf-a96800dd5ea4 -->","subChapters":[]},{"id":"47969809-130d-5f62-915b-91cf766b67d4","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 376ce9a6-8853-456b-85f0-a96c00ce2226 --><h3>Pregnancy and breastfeeding</h3><!-- end field 376ce9a6-8853-456b-85f0-a96c00ce2226 -->","summary":"","htmlStringContent":"<!-- begin item 15e7ebf4-2722-44ed-80c7-a96c00ce21e4 --><!-- begin field e140fe5d-45ee-4788-84a0-a96c00ce2226 --><h4>Pregnancy</h4><ul><li>The manufacturer advises to avoid oral montelukast unless essential.</li></ul><h4>Breastfeeding</h4><ul><li>The manufacturer advises to avoid oral montelukast unless essential.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF for Children, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/allergic-rhinitis/references/\">BNF 76, 2018</a>] </p><!-- end field e140fe5d-45ee-4788-84a0-a96c00ce2226 --><!-- end item 15e7ebf4-2722-44ed-80c7-a96c00ce21e4 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}